Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Therapeutic Advances in Urology
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Andersson, K.-E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Prospective pharmacologic therapies for the overactive bladder

Karl-Erik Andersson

Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA keanders{at}wfubmc.edu

Lower urinary tract symptoms (LUTS), overactive bladder syndrome (OAB) and detrusor overactivity (DO) are all conditions that can have major effects on quality of life and social functioning. Antimuscarinic drugs are first-line treatment-they often have good initial response rates, but adverse effects and decreasing efficacy cause long-term compliance problems, and alternatives are needed. The recognition of the functional contribution of the urothelium, the spontaneous myocyte activity during bladder filling, and the diversity of nerve transmitters has sparked interest in both peripheral and central modulation of LUTS/OAB/DO pathophysiology. There may be several new possibilities to treat LUTS/OAB/DO. β3-AR agonists (YM178), PDE 5 inhibitors (sildenafil, tadalafil, vardenafil), vitamin D analogs (elocalcitol), combinations ({alpha}1-AR antagonist + antimuscarinic), and drugs with a central mode of action (tramadol, aprepitant) all have Randomized controlled trial (RCT) documented efficacy. Which of these therapeutic principles will be developed to clinically useful treatments remains to be established.

Key Words: incontinence • detrusor overactivity • drug treatment

References

  • Andersson, K.E. (1993) Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 45: 253-308.[Medline] [Order article via Infotrieve]
  • Andersson, K.E. (1999) Pathways for Relaxation of detrusor smooth muscle, in Baskin, L.S. and Hayward, S.W. (eds) Advances in Bladder Research. Kluwer Academic/Plenum Publishers: New York, 241-252.
  • Andersson, K.E. (2002) Bladder activation: afferent mechanisms. Urology 59(5 Suppl 1): 43-50.[CrossRef][Medline] [Order article via Infotrieve]
  • Andersson, K.E. (2003) Storage and voiding symptoms: pathophysiologic aspects. Urology 62: 3-10.[Medline] [Order article via Infotrieve]
  • Andersson, K.E. (2007) LUTS treatment: future treatment options. Neurourol Urodyn 26: 934-47.[CrossRef][Medline] [Order article via Infotrieve]
  • Andersson, K.E. (2008) How many drugs for LUTS due to BPH are too many? J Urol 180: 811-2.[CrossRef][Medline] [Order article via Infotrieve]
  • Andersson, K.E. and Arner, A. (2004) Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 84: 935-86.[Abstract/Free Full Text]
  • Andersson, K.E., Chapple, C.R., Cardozo, L., Cruz, F., Hashim, H., Michel, M.C. et al. (in press) Pharmacological treatment of urinary incontinence, P. Abrams, L. Cardozo, S. Khoury, & A. Wein (eds) Incontinence, 4nd International Consultation on Incontinence. Plymbridge Distributors Ltd: Plymouth, UK.
  • Andersson, K.E. and Pehrson, R. (2003) CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention. Drugs 63: 2595-611.[CrossRef][Medline] [Order article via Infotrieve]
  • Aschkenazi, S., Botros, S., Miller, J., Gamble, T., Sand, P. and Goldberg, R. (2007) Overactive bladder symptoms are not related to detrusor overactivity. Neurourol Urodyn 26: 35.
  • Athanasopoulos, A., Gyftopoulos, K., Giannitsas, K., Fisfis, J., Perimenis, P. and Barbalias, G. (2003)
  • Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 169: 2253-6.
  • Badawi, J.K., Seja, T., Uecelehan, H., Honeck, P., Kwon, S.T., Bross, S. et al. (2007) Relaxation of human detrusor muscle by selective beta-2 and beta-3 agonists and endogenous catecholamines. Urology 69: 785-90.[CrossRef][Medline] [Order article via Infotrieve]
  • Biers, S.M., Reynard, J.M. and Brading, A.F. (2006) The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int 98: 1310-14.[CrossRef][Medline] [Order article via Infotrieve]
  • Birder, L.A. and de Groat, W.C. (2007) Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol 4: 46-54.[CrossRef][Medline] [Order article via Infotrieve]
  • Birder, L., Kullmann, F.A., Lee, H., Barrick, S., de Groat, W., Kanai, A. et al. (2007) Activation of urothelial transient receptor potential vanilloid 4 by 4alpha-phorbol 12,13-didecanoate contributes to altered bladder reflexes in the rat. J Pharmacol Exp Ther 323: 227-35.[Abstract/Free Full Text]
  • Carbone, A., Palleschi, G., Conte, A., Bova, G., Iacovelli, E., Bettolo, R.M. et al. (2006) Gabapentin treatment of neurogenic overactive bladder. Clin Neuropharmacol 29: 206-14.[CrossRef][Medline] [Order article via Infotrieve]
  • Chapple, C.R., Yamaguchi, O., Ridder, A., Liehne, J., Carl, S., Mattiassin, A. et al. (2008) Clinical proof of concept study (Blossom) shows novel B3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl 7: 239.
  • Christ, G.J. and Andersson, K.E. (2007) Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn 26: 948-54.[CrossRef][Medline] [Order article via Infotrieve]
  • Colli, E., Digesu, G.A. and Olivieri, L. (2007) Overactive bladder treatments in early phase clinical trials. Expert Opin Investig Drugs 16: 999-1007.[CrossRef][Medline] [Order article via Infotrieve]
  • Combrisson, H., Allix, S. and Robain, G. (2007) Influence of temperature on urethra to bladder micturition reflex in the awake ewe. Neurourol Urodyn 26: 290-5.[CrossRef][Medline] [Order article via Infotrieve]
  • Covenas, R., Martin, F., Belda, M., Smith, V., Salinas, P., Rivada, E. et al. (2003) Mapping of neurokinin-like immunoreactivity in the human brainstem. BMC Neurosci 4: 3.[CrossRef][Medline] [Order article via Infotrieve]
  • Crescioli, C., Ferruzzi, P., Caporali, A., Scaltriti, M., Bettuzzi, S., Mancina, R. et al. (2002) Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue. Mol Cell Endocrinol 198: 69-75.[CrossRef][Medline] [Order article via Infotrieve]
  • Crescioli, C., Ferruzzi, P., Caporali, A., Mancina, R., Comerci, A., Muratori, M. et al. (2003) Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog. Endocrinology 144: 3046-57.[Abstract/Free Full Text]
  • Crescioli, C., Ferruzzi, P., Caporali, A., Scaltriti, M., Bettuzzi, S., Mancina, R. et al. (2004) Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur J Endocrinol 150: 591-603.[Abstract]
  • Crescioli, C., Morelli, A., Adorini, L., Ferruzzi, P., Luconi, M., Vannelli, G.B. et al. (2005) Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab 90: 962-72.[Abstract/Free Full Text]
  • Cruz, F., Charrua, A., Cruz, C., Gharat, L., Gullapalli, S., Narayanan, S. et al. (2008) GRC 6211, a new oral TROV1 antagonist, decreases the frequency of bladder reflex contractions and noxious input in rats with acute or chronic cystitis. Eur Urol Suppl 7: 181.
  • Digesu, G.A., Khullar, V., Cardozo, L. and Salvatores, S. (2003) Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 22: 105-8.[CrossRef][Medline] [Order article via Infotrieve]
  • Drake, M.J. (2008) Emerging drugs for treatment of overactive bladder and detrusor overactivity. Expert Opin Emerg Drugs 13: 431-46.[CrossRef][Medline] [Order article via Infotrieve]
  • Du, S., Araki, I., Yoshiyama, M., Nomura, T. and Takeda, M. (2007) Transient receptor potential channel A1 involved in sensory transduction of rat urinary bladder through C-fiber pathway. Urology 70: 826-31.[CrossRef][Medline] [Order article via Infotrieve]
  • Fowler, C.J., Griffiths, D. and de Groat, W.C. (2008) The neural control of micturition. Nat Rev Neurosci 9: 453-66.[CrossRef][Medline] [Order article via Infotrieve]
  • Frazier, E.P., Mathy, M.J., Peters, S.L. and Michel, M.C. (2005) Does cyclic AMP mediate rat urinary bladder relaxation by isoproterenol? J Pharmacol Exp Ther 313: 260-7.[Abstract/Free Full Text]
  • Frazier, E.P., Peters, S.L., Braverman, A.S., Ruggieri Sr, M.R. and Michel, M.C. (2008) Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 377: 449-62.[CrossRef][Medline] [Order article via Infotrieve]
  • Fujimura, T., Tamura, K., Tsutsumi, T., Yamamoto, T., Nakamura, K., Koibuchi, Y. et al. (1999) Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle. J Urol 161: 680-5.[CrossRef][Medline] [Order article via Infotrieve]
  • Gee, N.S., Brown, J.P., Dissanayake, V.U., Offord, J., Thurlow, R. and Woodruff, G.N. (1996) The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 271: 5768-76.[Abstract/Free Full Text]
  • Gevaert, T., Vriens, J., Segal, A., Everaerts, W., Roskams, T., Talavera, K. et al. (2007) Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest 117: 3453-62.[CrossRef][Medline] [Order article via Infotrieve]
  • Giembycz, M.A. (2005) Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 5: 238-44.[CrossRef][Medline] [Order article via Infotrieve]
  • Gillespie, J.L. (2004) Phosphodiesterase-linked inhibition of nonmicturition activity in the isolated bladder. BJU Int 93: 1325-32.[CrossRef][Medline] [Order article via Infotrieve]
  • Gratzke, C., Streng, T., Waldkirch, E., Sigl, K., Stief, C., Andersson, K.E. et al. (2009) Transient Receptor Potential A1 (TRPA1) Activity in the Human Urethra-Evidence for a Functional Role for TRPA1 in the Outflow Region. Eur Urol 55: 696-704.
  • Green, S.A., Alon, A., Ianus, J., McNaughton, K.S., Tozzi, C.A. and Reiss, T.F. (2006) Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 176: 2535-40.[CrossRef][Medline] [Order article via Infotrieve]
  • Griffiths, D. (2007) Imaging bladder sensations. Neurourol Urodyn 26: 899-903.[CrossRef][Medline] [Order article via Infotrieve]
  • Griffiths, D. and Tadic, S.D. (2008) Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn 27: 466-74.[CrossRef][Medline] [Order article via Infotrieve]
  • Grond, S. and Sablotzki, A. (2004) Clinical pharmacology of tramadol. Clin Pharmacokinet 43: 879-923.[CrossRef][Medline] [Order article via Infotrieve]
  • Gu, B.J., Ishizuka, O., Igawa, Y., Nishizawa, O. and Andersson, K.E. (2000) Role of supraspinal tachykinins for micturition in conscious rats with and without bladder outlet obstruction. Naunyn Schmiedebergs Arch Pharmacol 361: 543-8.[CrossRef][Medline] [Order article via Infotrieve]
  • Hashim, H. and Abrams, P. (2004) Do symptoms of overactive bladder predict urodynamics detrusor overactivity? NeuroUrol Urodyn 23: 484-486.
  • Hicks, A., McCafferty, G.P., Riedel, E., Aiyar, N., Pullen, M., Evans, C. et al. (2007) GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther 323: 202-9.[Abstract/Free Full Text]
  • Hiragata, S., Ogawa, T., Hayashi, Y., Tyagi, P., Seki, S., Nishizawa, O. et al. (2007) Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats. Urology 70: 202-208.[Medline] [Order article via Infotrieve]
  • Holstege, G. (2005) Micturition and the soul. J Comp Neurol 493: 15-20.[CrossRef][Medline] [Order article via Infotrieve]
  • Hudman, D., Elliott, R.A. and Norman, R.I. (2000) K(ATP) channels mediate the beta(2)-adrenoceptor agonist-induced relaxation of rat detrusor muscle. Eur J Pharmacol 397: 169-76.[CrossRef][Medline] [Order article via Infotrieve]
  • Hyman, M.J., Groutz, A. and Blaivas, J.G. (2001) Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 166: 550-2.[CrossRef][Medline] [Order article via Infotrieve]
  • Igawa, Y., Yamazaki, Y., Takeda, H., Hayakawa, K., Akahane, M., Ajisawa, Y. et al. (1999) Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 126: 819-25.[CrossRef][Medline] [Order article via Infotrieve]
  • Igawa, Y., Yamazaki, Y., Takeda, H., Kaidoh, K., Akahane, M., Ajisawa, Y. et al. (2001) Relaxant effects of isoproterenol and selective beta3-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders. J Urol 165: 240-4.[CrossRef][Medline] [Order article via Infotrieve]
  • Irwin, D.E., Milsom, I., Hunskaar, S., Reilly, K., Kopp, Z., Herschorn, S. et al. (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50: 1306-14.[CrossRef][Medline] [Order article via Infotrieve]
  • Ishizuka, O., Igawa, Y., Lecci, A., Maggi, C.A., Mattiasson, A. and Andersson, K.E. (1994) Role of intrathecal tachykinins for micturition in unanaesthetized rats with and without bladder outlet obstruction. Br J Pharmacol 113: 111-6.[Medline] [Order article via Infotrieve]
  • Ishizuka, O., Igawa, Y., Nishizawa, O. and Andersson, K.E. (2000) Role of supraspinal tachykinins for volume- and L-dopa-induced bladder activity in normal conscious rats. Neurourol Urodyn 19: 101-9.[CrossRef][Medline] [Order article via Infotrieve]
  • Ishizuka, O., Mattiasson, A. and Andersson, K.E. (1995) Effects of neurokinin receptor antagonists on L-dopa induced bladder hyperactivity in normal conscious rats. J Urol 154: 1548-51.[CrossRef][Medline] [Order article via Infotrieve]
  • Kaidoh, K., Igawa, Y., Takeda, H., Yamazaki, Y., Akahane, S., Miyata, H. et al. (2002) Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol 168: 1247-52.[CrossRef][Medline] [Order article via Infotrieve]
  • Kaiho, Y., Nishiguchi, J., Kwon, D.D., Chancellor, M.B., Arai, Y., Snyder, P.B. et al. (2008) The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction. BJU Int 101: 615-20.[CrossRef][Medline] [Order article via Infotrieve]
  • Kaplan, S.A., Roehrborn, C.G., Rovner, E.S., Carlsson, M., Bavendam, T. and Guan, Z. (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296: 2319-28.[Abstract/Free Full Text]
  • Kim, Y.T., Kwon, D.D., Kim, J., Kim, D.K., Lee, J.Y. and Chancellor, M.B. (2004) Gabapentin for overactive bladder and nocturia after anticholinergic failure. Int Braz J Urol 30: 275-8.[Medline] [Order article via Infotrieve]
  • Lecci, A. and Maggi, C.A. (2001) Tachykinins as modulators of the micturition reflex in the central and peripheral nervous system. Regul Pept 101: 1-18.[CrossRef][Medline] [Order article via Infotrieve]
  • Lee, K.S., Choo, M.S., Kim, D.Y., Kim, J.C., Kim, H.J., Min, K.S. et al. (2005) Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 174: 1334-8.[CrossRef][Medline] [Order article via Infotrieve]
  • Lee, J.Y., Kim, H.W., Lee, S.J., Koh, J.S. and Suh, H.J. (2004) Chancellor MB.Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94: 817-20.[CrossRef][Medline] [Order article via Infotrieve]
  • Leon, L.A., Hoffman, B.E., Gardner, S.D., Laping, N.J., Evans, C., Lashinger, E.S. et al. (2008) Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats. J Pharmacol Exp Ther 326: 178-85.[Abstract/Free Full Text]
  • Longhurst, P.A., Briscoe, J.A., Rosenberg, D.J. and Leggett, R.E. (1997) The role of cyclic nucleotides in guinea-pig bladder contractility. Br J Pharmacol 121: 1665-72.[CrossRef][Medline] [Order article via Infotrieve]
  • Maneuf, Y.P., Gonzalez, M.I., Sutton, K.S., Chung, F.Z., Pinnock, R.D. and Lee, K. (2003) Cellular and molecular action of the putative GABA-mimetic, gabapentin. Cell Mol Life Sci 60: 742-50.[CrossRef][Medline] [Order article via Infotrieve]
  • Massaro, A.M. and Lenz, K.L. (2005) Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother 39: 77-85.[Abstract/Free Full Text]
  • McConnell, J.D., Roehrborn, C.G., Bautista, O.M., Andriole Jr, G.L., Dixon, C.M., Kusek, J.W. et al. (2003) Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387-98.[Abstract/Free Full Text]
  • McVary, K.T. (2007) A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther 29: 387-98.[CrossRef][Medline] [Order article via Infotrieve]
  • McVary, K.T., Roehrborn, C.G., Kaminetsky, J.C., Auerbach, S.M., Wachs, B., Young, J.M. et al. (2007a) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177: 1401-7.[CrossRef][Medline] [Order article via Infotrieve]
  • McVary, K.T., Monnig, W., Camps Jr, J.L., Young, J.M., Tseng, L.J. and van den Ende, G. (2007b) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177: 1071-7.[CrossRef][Medline] [Order article via Infotrieve]
  • Michel, M.C. and Vrydag, W. (2006) Alpha1-, alpha2-and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 147: S88-119.[CrossRef][Medline] [Order article via Infotrieve]
  • Mongin, G. (2007) Tramadol extended-release formulations in the management of pain due to osteoarthritis. Expert Rev Neurother 7: 1775-84.[CrossRef][Medline] [Order article via Infotrieve]
  • Morelli, A., Vignozzi, L., Filippi, S., Vannelli, G.B., Ambrosini, S., Mancina, R. et al. (2007) BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate 67: 234-47.[CrossRef][Medline] [Order article via Infotrieve]
  • Morita, T., Iizuka, H., Iwata, T. and Kondo, S. (2000) Function and distribution of beta3-adrenoceptors in rat, rabbit and human urinary bladder and external urethral sphincter. J Smooth Muscle Res 36: 21-32.[CrossRef][Medline] [Order article via Infotrieve]
  • Nishiguchi, J., Kwon, D.D., Kaiho, Y., Chancellor, M.B., Kumon, H., Snyder, P.B. et al. (2007) Suppression of detrusor overactivity in rats with bladder outlet obstruction by a type 4 phosphodiesterase inhibitor. BJU Int 99: 680-6.[CrossRef][Medline] [Order article via Infotrieve]
  • Nomiya, M. and Yamaguchi, O. (2003) A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 170: 649-53.[CrossRef][Medline] [Order article via Infotrieve]
  • Novara, G., Galfano, A., Ficarra, V. and Artibani, W. (2006) Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: A systematic review. Eur Urol 50: 675-83.[CrossRef][Medline] [Order article via Infotrieve]
  • Otsuka, A., Shinbo, H., Matsumoto, R., Kurita, Y. and Ozono, S. (2008) Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol 377: 473-81.[CrossRef][Medline] [Order article via Infotrieve]
  • Pehrson, R. and Andersson, K.E. (2003) Tramadol inhibits rat detrusor overactivity caused by dopamine receptor stimulation. J Urol 170: 272-5.[CrossRef][Medline] [Order article via Infotrieve]
  • Pehrson, R., Stenman, E. and Andersson, K.E. (2003) Effects of tramadol on rat detrusor overactivity induced by experimental cerebral infarction. Eur Urol 44: 495-9.[CrossRef][Medline] [Order article via Infotrieve]
  • Peters, S.L., Schmidt, M. and Michel, M.C. (2006) Rho kinase: a target for treating urinary bladder dysfunction? Trends Pharmacol Sci 27: 492-7.[CrossRef][Medline] [Order article via Infotrieve]
  • Roehrborn, C.G., Siami, P., Barkin, J., Damião, R., Major-Walker, K., Morrill, B. et al. (2008) CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. Urol 2008 179: 616-21.
  • Rovner, E.S., Kreder, K., Sussman, D.O., Kaplan, S.A., Carlsson, M., Bavendam, T. and Guan, Z. (2008) Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 180: 1034-41.[CrossRef][Medline] [Order article via Infotrieve]
  • Ruggieri Sr, M.R., Braverman, A.S. and Pontari, M.A. (2005) Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J Urol 174: 1743-8.[CrossRef][Medline] [Order article via Infotrieve]
  • Sacco, E., Pinto, F. and Bassi, P. (2008) Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences. Int Urogynecol J Pelvic Floor Dysfunct 19: 583-98.[CrossRef][Medline] [Order article via Infotrieve]
  • Safarinejad, M.R. and Hosseini, S.Y. (2006) Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind, placebo-controlled, randomized study. Br J Clin Pharmacol 61: 456-63.[CrossRef][Medline] [Order article via Infotrieve]
  • Saffroy, M., Torrens, Y., Glowinski, J. and Beaujouan, J.C. (2003) Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience 116: 761-73.[CrossRef][Medline] [Order article via Infotrieve]
  • Sairam, K., Kulinskaya, E., McNicholas, T.A., Boustead, G.B. and Hanbury, D.C. (2002) Sildenafil influences lower urinary tract symptoms. BJU Int 90: 836-9.[CrossRef][Medline] [Order article via Infotrieve]
  • Schröder, A., Colli, E., Maggi, M. and Andersson, K.E. (2006) Effects of a vitamin D3 analogue in a rat model of bladder outflow obstruction. BJU Int 98: 637-42.[CrossRef][Medline] [Order article via Infotrieve]
  • Seki, S., Erickson, K.A., Seki, M., Nishizawa, O., Igawa, Y., Ogawa, T. et al. (2005) Elimination of rat spinal neurons expressing neurokinin 1 receptors reduces bladder overactivity and spinal c-fos expression induced by bladder irritation. Am J Physiol Renal Physiol 288: F466-73.[Abstract/Free Full Text]
  • Singh, S.K., Agarwal, M.M., Batra, Y.K., Kishore, A.V. and Mandal, A.K. (2008) Effect of lumbar-epidural administration of tramadol on lower urinary tract function. Neurourol Urodyn 27: 65-70.[CrossRef][Medline] [Order article via Infotrieve]
  • Steers, W.D., Herschorn, S., Kreder, K.J., Moore, K., Strohbehn, K., Yalcin, I. et al. (2007) Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int 100: 337-45.[CrossRef][Medline] [Order article via Infotrieve]
  • Stief, C.G., Porst, H., Neuser, D., Beneke, M. and Ulbrich, E. (2008) A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53: 1236-44.[CrossRef][Medline] [Order article via Infotrieve]
  • Streng, T., Axelsson, H.E., Hedlund, P., Andersson, D.A., Jordt, S.E., Bevan, S. et al. (2008) Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder. Eur Urol 53: 391-9.[CrossRef][Medline] [Order article via Infotrieve]
  • Striano, P. and Striano, S. (2008) Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy. Drugs Today ( Barc) 44: 353-68.[Medline] [Order article via Infotrieve]
  • Takeda, M., Obara, K., Mizusawa, T., Tomita, Y., Arai, K., Tsutsui, T. et al. (1999) Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 288: 1367-73.[Abstract/Free Full Text]
  • Takasu, T., Ukai, M., Sato, S., Matsui, T., Nagase, I., Maruyama, T. et al. (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321: 642-7.[Abstract/Free Full Text]
  • Takeda, H., Yamazaki, Y., Igawa, Y., Kaidoh, K., Akahane, S., Miyata, H. et al. (2002) Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn 21: 558-65.[CrossRef][Medline] [Order article via Infotrieve]
  • Truss, M.C., Stief, C.G., Uckert, S., Becker, A.J., Schultheiss, D., Machtens, S. et al. (2000) Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol 18: 439-443.[CrossRef][Medline] [Order article via Infotrieve]
  • Truss, M.C., Stief, C.G., Uckert, S., Becker, A.J., Wefer, J., Schultheiss, D. et al. (2001) Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 19: 344-350.[CrossRef][Medline] [Order article via Infotrieve]
  • Uchida, H., Shishido, K., Nomiya, M. and Yamaguchi, O. (2005) Involvement of cyclic AMP-dependent and -independent mechanisms in the relaxation of rat detrusor muscle via beta-adrenoceptors. Eur J Pharmacol 518: 195-202.[CrossRef][Medline] [Order article via Infotrieve]
  • Uckert, S., Kuthe, A., Jonas, U. and Stief, C.G. (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166: 2484-90.[CrossRef][Medline] [Order article via Infotrieve]
  • Woods, M., Carson, N., Norton, N.W., Sheldon, J.H. and Argentieri, T.M. (2001) Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol 166: 1142-7.[CrossRef][Medline] [Order article via Infotrieve]
  • Yoshimura, N., Kaiho, Y., Miyazato, M., Yunoki, T., Tai, C., Chancellor, M.B. et al. (2008) Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol 377: 437-48.[CrossRef][Medline] [Order article via Infotrieve]

This version was published on June 1, 2009

Therapeutic Advances in Urology, Vol. 1, No. 2, 71-83 (2009)
DOI: 10.1177/1756287209103937
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Andersson, K.-E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?